5 Key Takeaways
-
1
Surgeons are exploring the benefits of targeting both trabecular and uveoscleral outflow pathways in glaucoma treatment.
-
2
Uveoscleral outflow agents have shown greater efficacy compared to trabecular outflow in pharmacotherapy.
-
3
Current surgical practices predominantly focus on trabecular outflow, despite the potential benefits of uveoscleral interventions.
-
4
The AlloFlo and AlloSpan technologies aim to enhance both uveoscleral and trabecular outflow in glaucoma patients.
-
5
A comprehensive approach addressing both outflow pathways may improve outcomes for moderate to advanced glaucoma patients.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.